Announced Thu, 13 Aug · 15:48 IST
Titan Biotech Q1 FY27: PAT up 53% YoY at Rs 9.46 cr, revenue grows 27%
Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+5.1%1-day move
₹392.05
prior close
₹411.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
—+0.0+0.0—+5.1+2.4+1.4+0.2+2.3—————
Up moveDown movePending
AI summary
Titan Biotech posted Q1 FY27 (June 2026) standalone revenue of Rs 59.17 cr, up 27.2% from Rs 46.50 cr YoY. PAT rose 53.5% to Rs 9.46 cr versus Rs 6.16 cr. PBT grew 57% to Rs 12.73 cr. Total expenses at Rs 48.25 cr. Consolidated PAT (incl associates Peptech and Titan Media) was Rs 10.86 cr. Auditor gave a clean limited review. Freight reclassification noted in current year.
Likely market impact
Strong topline and bottomline growth with margin expansion. Clean auditor review supports positive earnings momentum for shareholders.